Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - April 2014

The National Institute of Health and Care Excellence (NICE) has published new guidance for the month of April 2014. This month there is one clinical guideline that impacts upon primary care.

The Pressure ulcers clinical guideline offers evidence-based advice on the prevention and management of pressure ulcers. It updates and replaces two previous guidelines (CG7 and CG29). The guideline recommends risk assessment tools and strategies to aid prevention as well as management of existing ulcers. Recommendations are made specifically for adults and also neonates, infants, children and young people.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - April 2014' on Email Share 'NICE Guidance - April 2014' on Delicious Share 'NICE Guidance - April 2014' on Digg Share 'NICE Guidance - April 2014' on Facebook Share 'NICE Guidance - April 2014' on Google+ Share 'NICE Guidance - April 2014' on reddit Share 'NICE Guidance - April 2014' on StumbleUpon Share 'NICE Guidance - April 2014' on Twitter

Drug Safety Update - April 2014

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for April 2014 (PDF).

This issue reports an update to the Yellow Card form used for collecting suspected adverse reactions with the aim of improving our understanding of a medicine’s effect during pregnancy. The forms will be update to collect data about a current pregnancy including the date of last menstrual period and expected date of delivery. The "additional information" field can also be used to include any information on previous pregnancies, dates and findings of ultrasonography and the dates when a woman started or stopped taking any other medicines and supplements during pregnancy (including folic acid).

This issue also contains a reminder about drug-name confusions at the point of dispensing. A previous Drug Safety Update highlighted this issue but this issue notes that there have been recent errors relating to bumetanide and buspirone. It is also noted that the packaging of some morphine sulfate products is being updated to better highlight the strength of the medicine on the pack.

Action: Clinicians will find this publication to be a useful review of current issues in drug safety.

Share 'Drug Safety Update - April 2014' on Email Share 'Drug Safety Update - April 2014' on Delicious Share 'Drug Safety Update - April 2014' on Digg Share 'Drug Safety Update - April 2014' on Facebook Share 'Drug Safety Update - April 2014' on Google+ Share 'Drug Safety Update - April 2014' on reddit Share 'Drug Safety Update - April 2014' on StumbleUpon Share 'Drug Safety Update - April 2014' on Twitter

NICE Guidance - March 2014

The National Institute of Health and Care Excellence (NICE) has published new guidance for the month of March 2014. This month there is one public health guideline that impacts upon primary care.

The Contraceptive services with a focus on young people public health guideline recommends that young men and women should be given advice and information on all types of contraception to help them choose the best method for their needs and lifestyle. This makes it more likely that contraception will be used effectively. The recommendations apply to commissioners, managers and practitioners who have a direct or indirect role in, and responsibility for, contraceptive services.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - March 2014' on Email Share 'NICE Guidance - March 2014' on Delicious Share 'NICE Guidance - March 2014' on Digg Share 'NICE Guidance - March 2014' on Facebook Share 'NICE Guidance - March 2014' on Google+ Share 'NICE Guidance - March 2014' on reddit Share 'NICE Guidance - March 2014' on StumbleUpon Share 'NICE Guidance - March 2014' on Twitter

Drug Safety Update - March 2014

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2014 (PDF).

This issue contains drug safety advice informing clinicians of a theoretical interaction between orlistat and antiretroviral HIV medicines. Orlistat may reduce the absorption of these medicines and as such reduce efficacy. It is recommended that orlistat is only used in patients taking antiretroviral HIV medicines after careful consideration. It is also recommended that individuals interested in purchasing orlistat (Alli®) over the counter should consult their doctor before starting treatment.

This section also reminds clinicians that St John’s wort interacts with hormonal contraceptives. Two Yellow Card reports have been submitted recently regarding women using the etonogestrel implant (Implanon® or Nexplanon®) who used St John’s wort and subsequently had an unplanned pregnancy. Clinicians are advised to tell women taking hormonal contraceptives for pregnancy prevention not to take herbal products containing St John’s wort.

The stop press section contains additional information about the recently announced restricted indications and new monitoring requirements for strontium ranelate in light of increased cardiovascular risks and also the new restricted use and monitoring requirements for methysergide in light of serious fibrotic reactions. Methysergide is currently only available in the UK via unlicensed imports. The stop press section also advises that the updated packaging design for dorzolamide/timolol (Cosopt®) preservative-free eye drops, which aims to prevent inadvertent eye injuries, is now available.

Finally, in other information, advice disseminated via the NHS Central Alerting System in January regarding combined hormonal contraception is clarified. Annexes sent with this alert recommend that women at higher risk of VTE use "a non-hormonal form of contraception" when it ought to have stated "that a different form of contraception should be used". This change indicates that progestogen-only contraceptives as well as non-hormonal methods are suitable options.

Action: Clinicians will find this publication to be a useful review of current issues in drug safety.

Share 'Drug Safety Update - March 2014' on Email Share 'Drug Safety Update - March 2014' on Delicious Share 'Drug Safety Update - March 2014' on Digg Share 'Drug Safety Update - March 2014' on Facebook Share 'Drug Safety Update - March 2014' on Google+ Share 'Drug Safety Update - March 2014' on reddit Share 'Drug Safety Update - March 2014' on StumbleUpon Share 'Drug Safety Update - March 2014' on Twitter

MTRAC Reviews - March 2014

MTRAC issued two new Commissioning Support reviews in March 2014. The reviews cover denosumab and rifaximin.

The denosumab (Prolia®) summary advises that this drug is suitable for restricted prescribing in primary care, following secondary care initiation and stabilisation of treatment. The review notes that this medicine has relatively strong evidence but a lower place in therapy as recommended by NICE guidance.

The rifaximin (Targaxan®) summary advises that this drug is suitable for restricted prescribing in primary care, following secondary care initiation and stabilisation and with the guidance of a shared care agreement. The review notes that this medicine has relatively strong evidence but a lower place in therapy after existing treatment options were inadequate or inappropriate.

Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.

Share 'MTRAC Reviews - March 2014' on Email Share 'MTRAC Reviews - March 2014' on Delicious Share 'MTRAC Reviews - March 2014' on Digg Share 'MTRAC Reviews - March 2014' on Facebook Share 'MTRAC Reviews - March 2014' on Google+ Share 'MTRAC Reviews - March 2014' on reddit Share 'MTRAC Reviews - March 2014' on StumbleUpon Share 'MTRAC Reviews - March 2014' on Twitter

« Older Posts

Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 725,590 spam comments.

atomic-wealth